• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有类酪氨酸激酶结构域的新型细胞表面受体家族。

A novel family of cell surface receptors with tyrosine kinase-like domain.

作者信息

Masiakowski P, Carroll R D

机构信息

Regeneron Pharmaceuticals, Tarrytown, New York 10591-6707.

出版信息

J Biol Chem. 1992 Dec 25;267(36):26181-90.

PMID:1334494
Abstract

Human cDNA clones encoding two novel proteins with a region strongly homologous to the tyrosine kinase domain of growth factor receptors, in particular of the Trk family, were obtained by a polymerase chain reaction-based approach. These proteins, Ror1 and Ror2, share 58% overall amino acid identity and a structure indicative of cell surface molecules. A secretion signal sequence and a transmembrane domain delimit the extracellular portion, which contains immunoglobulin-like, cysteine-rich, and kringle domains. The cytoplasmic portion contains the tyrosine kinase-like domain which (in Ror2) appears to be associated with protein kinase activity in vitro, followed by serine/threonine- and proline-rich motifs. Partial nucleotide sequences of the rat genes reveal striking evolutionary conservation of the proteins between human and rat. The level of expression of the rat genes is high in the head and body of early embryo and decreases dramatically after embryonic day 16. Based on these data, Ror1 and Ror2 appear to define a new developmentally regulated family of cell surface receptors for unidentified ligands.

摘要

通过基于聚合酶链反应的方法,获得了编码两种新型蛋白质的人cDNA克隆,这些蛋白质具有与生长因子受体(特别是Trk家族)的酪氨酸激酶结构域高度同源的区域。这些蛋白质Ror1和Ror2的氨基酸序列总体一致性为58%,具有细胞表面分子的结构特征。分泌信号序列和跨膜结构域界定了细胞外部分,该部分包含免疫球蛋白样、富含半胱氨酸和kringle结构域。细胞质部分包含酪氨酸激酶样结构域(在Ror2中),体外实验表明其似乎与蛋白激酶活性相关,随后是富含丝氨酸/苏氨酸和脯氨酸的基序。大鼠基因的部分核苷酸序列显示,人与大鼠之间的蛋白质具有显著的进化保守性。大鼠基因在早期胚胎的头部和身体中表达水平较高,在胚胎第16天后急剧下降。基于这些数据,Ror1和Ror2似乎定义了一个新的受发育调控的细胞表面受体家族,其配体尚未明确。

相似文献

1
A novel family of cell surface receptors with tyrosine kinase-like domain.具有类酪氨酸激酶结构域的新型细胞表面受体家族。
J Biol Chem. 1992 Dec 25;267(36):26181-90.
2
Identification and characterization of rat Ror1 and Ror2 genes in silico.大鼠Ror1和Ror2基因的电子克隆与特征分析
Int J Mol Med. 2005 Mar;15(3):533-8.
3
The receptor tyrosine kinase Ror2 associates with the melanoma-associated antigen (MAGE) family protein Dlxin-1 and regulates its intracellular distribution.受体酪氨酸激酶Ror2与黑色素瘤相关抗原(MAGE)家族蛋白Dlxin-1结合,并调节其细胞内分布。
J Biol Chem. 2003 Aug 1;278(31):29057-64. doi: 10.1074/jbc.M302199200. Epub 2003 May 16.
4
Comparative genomics on ROR1 and ROR2 orthologs.ROR1和ROR2直系同源基因的比较基因组学
Oncol Rep. 2005 Nov;14(5):1381-4. doi: 10.3892/or.14.5.1381.
5
Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases.具有kringle结构域的肌肉特异性trk相关受体定义了一类独特的受体酪氨酸激酶。
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2895-9. doi: 10.1073/pnas.90.7.2895.
6
Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.一种与fms家族密切相关的新型人类受体型酪氨酸激酶基因(flt)的核苷酸序列及表达
Oncogene. 1990 Apr;5(4):519-24.
7
Molecular cloning of the cDNA encoding a receptor tyrosine kinase-related molecule with a catalytic region homologous to c-met.
Int J Cell Cloning. 1992 Sep;10(5):309-14. doi: 10.1002/stem.5530100509.
8
A novel tyrosine kinase, hyk, expressed in murine embryonic stem cells.一种在小鼠胚胎干细胞中表达的新型酪氨酸激酶——hyk。
Biochem Biophys Res Commun. 1992 Dec 30;189(3):1747-53. doi: 10.1016/0006-291x(92)90280-x.
9
Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family.具有相关表达谱的不同大鼠基因定义了一个TIE受体酪氨酸激酶家族。
Oncogene. 1993 Jun;8(6):1631-7.
10
Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs expressed in MCF-7 breast-cancer cells.对包括在MCF-7乳腺癌细胞中表达的四种成纤维细胞生长因子受体(FGF受体)mRNA在内的酪氨酸激酶mRNA的分析。
Int J Cancer. 1992 Feb 20;50(4):598-603. doi: 10.1002/ijc.2910500419.

引用本文的文献

1
Targeting Wnt-driven metabolic adaptations in cancer: integrating glycolysis, glutaminolysis, IDO1-mediated immune evasion, and therapeutic delivery strategies.靶向癌症中Wnt驱动的代谢适应性:整合糖酵解、谷氨酰胺分解、吲哚胺2,3-双加氧酶1介导的免疫逃逸及治疗递送策略
Front Cell Dev Biol. 2025 Aug 22;13:1622218. doi: 10.3389/fcell.2025.1622218. eCollection 2025.
2
Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk.血浆蛋白质组学分析可识别与阿尔茨海默病风险相关的蛋白质和信号通路。
Alzheimers Dement. 2025 Aug;21(8):e70579. doi: 10.1002/alz.70579.
3
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate.
新型ROR2特异性条件活性生物抗体药物偶联物ozuriftamab vedotin(BA3021)的临床前开发
MAbs. 2025 Dec;17(1):2490078. doi: 10.1080/19420862.2025.2490078. Epub 2025 Apr 9.
4
Targeting ROR2 homooligomerization disrupts ROR2-dependent signaling and suppresses stem-like cell properties of human breast adenocarcinoma.靶向ROR2同源寡聚化可破坏ROR2依赖的信号传导,并抑制人乳腺腺癌的干细胞样特性。
iScience. 2024 Dec 13;28(1):111589. doi: 10.1016/j.isci.2024.111589. eCollection 2025 Jan 17.
5
Therapeutic advances in the targeting of ROR1 in hematological cancers.血液系统恶性肿瘤中靶向ROR1的治疗进展。
Cell Death Discov. 2024 Nov 17;10(1):471. doi: 10.1038/s41420-024-02239-1.
6
Therapeutic advances of targeting receptor tyrosine kinases in cancer.靶向治疗癌症受体酪氨酸激酶的治疗进展。
Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.
7
Heterogeneous Profile of ROR1 Protein Expression across Tumor Types.跨肿瘤类型的ROR1蛋白表达的异质性概况。
Cancers (Basel). 2024 May 15;16(10):1874. doi: 10.3390/cancers16101874.
8
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.革新小儿神经母细胞瘤治疗:揭示精准干预的新分子靶点。
Front Cell Dev Biol. 2024 Mar 27;12:1353860. doi: 10.3389/fcell.2024.1353860. eCollection 2024.
9
ROR1-AS1 might promote in vivo and in vitro proliferation and invasion of cholangiocarcinoma cells.ROR1-AS1 可能促进胆管癌细胞的体内和体外增殖和侵袭。
BMC Cancer. 2023 Sep 28;23(1):912. doi: 10.1186/s12885-023-11412-1.
10
Protein Kinases and their Inhibitors Implications in Modulating Disease Progression.蛋白激酶及其抑制剂对疾病进展调控的影响
Protein J. 2023 Dec;42(6):621-632. doi: 10.1007/s10930-023-10159-9. Epub 2023 Sep 28.